BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX)’s share price fell 4.6% on Tuesday . The company traded as low as $2.88 and last traded at $2.88, with a volume of 159,963 shares. The stock had previously closed at $3.02.

A number of research firms have recently weighed in on BCRX. Jefferies Group upgraded BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $14.00 price target for the company in a report on Wednesday, June 1st. FBR & Co restated a “buy” rating and set a $6.00 target price on shares of BioCryst Pharmaceuticals in a report on Wednesday, July 6th. Zacks Investment Research cut BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, April 11th. Finally, HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of BioCryst Pharmaceuticals in a report on Monday, May 9th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and six have issued a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $9.70.

The firm’s market cap is $220.34 million. The firm has a 50 day moving average of $3.07 and a 200 day moving average of $3.68.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Thursday, May 5th. The biotechnology company reported ($0.31) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by $0.08. The company earned $4.82 million during the quarter, compared to analysts’ expectations of $5.42 million. The company’s revenue was down 29.4% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.21) EPS. On average, equities research analysts forecast that BioCryst Pharmaceuticals Inc. will post ($1.06) earnings per share for the current fiscal year.

A number of institutional investors have added to or reduced their stakes in BCRX. Morgan Stanley raised its position in BioCryst Pharmaceuticals by 13.9% in the fourth quarter. Morgan Stanley now owns 103,804 shares of the biotechnology company’s stock valued at $1,071,000 after buying an additional 12,646 shares during the last quarter. Globeflex Capital L P purchased a new stake in shares of BioCryst Pharmaceuticals during the fourth quarter valued at approximately $1,241,000. Finally, Jennison Associates LLC raised its stake in shares of BioCryst Pharmaceuticals by 1.8% in the fourth quarter. Jennison Associates LLC now owns 1,348,563 shares of the biotechnology company’s stock valued at $13,917,000 after buying an additional 24,014 shares in the last quarter.

BioCryst Pharmaceuticals, Inc (BioCryst) is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment rare diseases. The Company uses X-ray crystallography, computer modeling of molecular structures and advanced chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.